Alcon Stock

Alcon EBIT Growth

The Year-over-Year EBIT Growth of Alcon (ALC.SW) as of Aug 3, 2026 is 0.83 %. In the previous year, Year-over-Year EBIT Growth was 38.39 % — a change of -97.84% (lower).

EBIT Growth

0.83 %

YoY

-97.84%

Last updated:

Year-over-Year EBIT Growth of Alcon is 2026 0.83 % . Year-over-Year EBIT Growth of Alcon was 2025 38.39 % . It decreases by -97.84% lower compared to the previous year.
Access this data via the Eulerpool API

Alcon Stock analysis

What does Alcon do? Alcon AG is a leading company in ophthalmology with more than 70 years of experience in this industry. The company was founded in 1945 by Robert Alexander and William Conner and has its headquarters in Geneva, Switzerland. Alcon AG has been part of the Novartis Group since 2019 and is a leader in the production of ophthalmic products. The business model of Alcon AG is based on the manufacturing and sale of ophthalmic products. The company offers medical products such as contact lenses, surgical instruments, eye drops, and intraocular lenses. Alcon AG specializes in the development of products that can be used for various eye diseases. The company provides a wide range of products that can be used by ophthalmologists and opticians. The various divisions of Alcon AG include eye care products, surgical products, and diagnostic products. Eye care products, such as contact lenses, offer consumers a safe and easy way to correct their vision. Surgical products include a wide range of instruments used in eye surgeries. Diagnostic products help identify eye diseases and support treatment. Alcon AG specializes in the development of products for the treatment of eye diseases. These include conditions such as cataracts, glaucoma, and age-related macular degeneration. The company offers various products that can be used for these conditions, such as eye drops to reduce elevated eye pressure in glaucoma. It has also developed a wide range of products for refractive correction, allowing people to improve their vision. Alcon AG works closely with leading ophthalmologists and opticians to optimize its product development. This close collaboration ensures that Alcon AG's products meet the needs of patients and provide them with high safety and effectiveness. With its innovative products and technologies, Alcon AG aims to improve the quality of life for patients and provide them with optimal care and treatment. Overall, Alcon AG is a leading company in ophthalmology, offering its customers a wide range of innovative and high-quality products. From diagnosis to care to surgical interventions, Alcon AG's product range covers all areas of ophthalmology. The company is known for its research and development and is constantly working towards advancing ophthalmology. Through its continuous innovation and customer orientation, Alcon AG has established a strong position in the healthcare industry and will continue to introduce new products and technologies in the future. Alcon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alcon stock

Year-over-Year EBIT Growth of Alcon is 0.83 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Alcon since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Alcon historically and in real time.

Access this data via the Eulerpool API

Growth — Alcon

All Key Metrics — Alcon